To include your compound in the COVID-19 Resource Center, submit it here.

Refinement wanted

Refinement wanted

As mandated by the FDA Amendments Act of 2007, FDA last week released its first quarterly report on potential signals of risk for marketed drugs. Under FDAAA, the agency must report new safety information or potential signals of a serious risk identified by the adverse event reporting system (AERS) each quarter. The report included a table listing more than 20

Read the full 633 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers